Feladilimab

Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab) ; GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer[1].

Product Specifications

CAS Number

[2252518-85-5]

Product Name Alternative

Anti-ICOS/CD278 Reference Antibody (feladilimab) ; GSK3359609

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/feladilimab.html

Purity

99.255

Solubility

10 mM in DMSO

Smiles

[Feladilimab]

Molecular Weight

(145.52 kDa)

References & Citations

[1]Offidani M, et al. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Des Devel Ther. 2021 Jun 2;15:2401-2415.|[2]Steeghs N, et al. Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development. Clin Transl Sci. 2022 Nov;15 (11) :2625-2639.